CN102058557A - Multicomponent sustained-release preparation and preparation method thereof - Google Patents
Multicomponent sustained-release preparation and preparation method thereof Download PDFInfo
- Publication number
- CN102058557A CN102058557A CN2009102283076A CN200910228307A CN102058557A CN 102058557 A CN102058557 A CN 102058557A CN 2009102283076 A CN2009102283076 A CN 2009102283076A CN 200910228307 A CN200910228307 A CN 200910228307A CN 102058557 A CN102058557 A CN 102058557A
- Authority
- CN
- China
- Prior art keywords
- release
- slow
- preparation
- pastille
- slow releasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a multicomponent sustained-release preparation and a preparation method thereof. An isolation layer is arranged between a sustained-release part and a quick release part in the sustained-release preparation to effectively isolate the interaction of a sustained-release tablet core and an external quick release coat, the external quick release part is quickly released completely, the isolation layer is quickly dissolved when meeting an aqueous medium, and the release of the sustained-release tablet core is not influenced. The technology can be applied to compound sustained-release preparations as required.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of multicomponent slow releasing preparation and method for making thereof, relate more specifically to a kind of multicomponent slow releasing preparation and method for making of forming by internal layer slow-released part and outer immediate release section thereof.The stripping rapidly of the outer Chinese medicine of this slow releasing preparation, the internal layer Chinese medicine can slowly discharge, and does not disturb mutually.
Background technology
In the compound recipe sustained-release preparation, the component that half-life difference is big for collaborative release administration, often is made up of slow release and rapid release two parts.Wherein slow-released part is that water soluble drug and dosage are big, and immediate release section is that poorly water soluble drugs and dosage are little, should adopt multilamellar slow releasing tablet technology, the inside and outside synusia of slow release label and rapid release clothing layer, and like this, the sheet sub-volumes is little, can make special-shaped sheet, and is attractive in appearance, and compliance is good.But, there is the mutual interference problem of slow release and rapid release at present, the immediate release drug part is owing to be subjected to the influence of internal layer slow-released part, and the full stripping of very difficult arrival, the slow releasing pharmaceutical part, owing to be subjected to the influence of outer medicine, initial drug discharges influenced, and slow-released part release profiles difference is big in the release profiles of slow release label and the compound slow release preparation.
The medicine example hydrochloric acid metformin that water solublity dosage is big, nicotinic acid etc., the preparation slow releasing tablet should adopt the gel skeleton technology, and gel matrix tablet chance water promptly expands and then stops the medicine stripping to reach the slow release purpose.Kind by regulating the high-molecular bone frame material, consumption and in conjunction with matrix tablet outer wrapping one deck hydrophobic polymer layer can effectively be controlled the release of medicine.
When the little medicine of above-mentioned slow releasing preparation and long half time dosage was made the compound preparation administering drug combinations, the medicine that long half time dosage is little should not be made slow releasing preparation, should make the rapid release conventional formulation, to reach the purpose of collaborative release administration in the body.Therefore, this type of compound preparation should be made the ectonexine compound preparation, and skin discharges rapidly, and internal layer slowly discharges, but if matrix sustained release tablet, skin is directly added medicine to, the mutual interference of ectonexine phase, outer medicine can not reach full stripping, and the initial release of internal layer medicine is also influenced.
The example of the medicine that above-mentioned long half time dosage is little has sulfonylureas such as glimepiride, gliquidone, thiazolidinediones medicine such as pioglitazone, rosiglitazone, statins such as lovastatin, simvastatin, atorvastatin, fibrate such as FENOBRATE top grade.
Summary of the invention
In order to address the above problem, the purpose of this invention is to provide a kind of multicomponent slow releasing preparation and preparation method, add a sealing coat by slow-released part and immediate release section centre in this slow releasing preparation, make the rapid release of immediate release section and discharge complete, the release profiles of slow-released part is similar to slow release label release profiles, and slow-released part and immediate release section are not disturbed mutually.
Sealing coat is made up of high molecular weight water soluble polymer, can effectively isolate the interaction of slow release label and outer rapid release clothing layer, and self meets aqueous medium and peel off dissolving rapidly, does not influence the release of slow release label.This technology can be applicable in the compound slow release preparation of any needs.
The sealing coat of preparation of the present invention is that the mixture by water soluble polymer constitutes, and water-soluble high-molecular substance is meant, can be at the outer polymer substance that forms homogeneous film and can be dissolved in aqueous medium of tablet.As, water-soluble cellulose ether, water-soluble polyethylene radical derivative, alkylene oxide polymer etc.
The example of water-soluble cellulose ether has methylcellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose etc.; The example of water-soluble polyethylene radical derivative has polyvinylpyrrolidone, polyvinyl alcohol etc.; The example of alkylene oxide polymer has Polyethylene Glycol, polypropylene glycol etc.Wherein preferred especially hydroxypropyl emthylcellulose and polyvinylpyrrolidone.
This water soluble polymer not only can use separately also and can mix use.
Sealing coat part by water soluble polymer (as sodium alginate; polyvinylpyrrolidone; hydroxyethyl-cellulose; hydroxypropyl methylcellulose; sodium carboxymethyl cellulose; chitin; polyvinyl alcohol); plasticizer is (as propylene glycol; Polyethylene Glycol; triethyl citrate; tributyl citrate; the acetyl group triethyl citrate; the acetyl group tributyl citrate; dimethyl phthalate; diethyl phthalate; phthalic acid dibutyl ester; certain herbaceous plants with big flowers two dibutyl phthalates); antiplastering aid is (as Pulvis Talci; micropowder silica gel; magnesium stearate) forms.
Multicomponent slow releasing preparation of the present invention, slow release label and rapid release clothing layer contained drug composition are different, select the big drug regimen of half-life difference especially for use, the half-life of slow release label Chinese medicine is short, dosage is big, and the drug half-life in the rapid release clothing layer is long, dosage is little.
The slow releasing tablet core segment comprises by the matrix tablet of the pastille of the matrix tablet of pastille or outer bag one release membranes and forming.Framework material can be water soluble polymer (as sodium alginate, xanthan gum, hydroxyethyl-cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, chitin, polyvinyl alcohol) or water-insoluble high polymer (as ethyl cellulose, acrylic resin) or fatty acid and ester (as stearic acid, Brazil wax, glyceryl monostearate, octadecanol) thereof.Slow-release material in the coatings can be ethyl cellulose, cellulose acetate, acrylic resin.Plasticizer can be propylene glycol, Polyethylene Glycol, triethyl citrate, tributyl citrate, acetyl group triethyl citrate, acetyl group tributyl citrate, dimethyl phthalate, diethyl phthalate, phthalic acid dibutyl ester, certain herbaceous plants with big flowers two dibutyl phthalates.Porogen can be Polyethylene Glycol, polyvidone, sucrose, salt, hydroxyethyl-cellulose, hydroxypropyl methylcellulose.
Rapid release pastille clothing layer segment is by medicine; water soluble polymer is (as sodium alginate; polyvinylpyrrolidone; hydroxyethyl-cellulose; hydroxypropyl methylcellulose; sodium carboxymethyl cellulose; chitin; polyvinyl alcohol); plasticizer is (as propylene glycol; Polyethylene Glycol; triethyl citrate; tributyl citrate; the acetyl group triethyl citrate; the acetyl group tributyl citrate; dimethyl phthalate; diethyl phthalate; phthalic acid dibutyl ester; certain herbaceous plants with big flowers two dibutyl phthalates) antiplastering aid is (as Pulvis Talci; micropowder silica gel; magnesium stearate); cosolvent (sodium lauryl sulphate; polysorbate; span) forms.
When carrying out testing in vitro, rapid release pastille clothing layer all was stripped in 5～15 minutes in the medium, and dissolution in vitro and conventional formulation do not have significant difference; The release characteristic of slow release label and its single component slow releasing preparation do not have significant difference.
Description of drawings
Fig. 1 multicomponent slow releasing preparation sketch map
Pioglitazone hydrochloride stripping curve in the conventional sheet of Fig. 2 pioglitazone metformin slow releasing tablet and pioglitazone hydrochloride
Metformin hydrochloride release profiles in Fig. 3 pioglitazone metformin slow releasing tablet and the diabecron sustained-release tablet
Glimepiride stripping curve in the conventional sheet of Fig. 4 glimepiride metformin slow releasing tablet and glimepiride
Metformin hydrochloride release profiles in Fig. 5 glimepiride metformin slow releasing tablet and the diabecron sustained-release tablet
Simvastatin stripping curve in the conventional sheet of Fig. 6 simvastatin niacin sustained release tablet and simvastatin
Nicotinic acid release profiles in Fig. 7 simvastatin niacin sustained release tablet and the niacin slow-release tablet
Embodiment
The present invention will be described in more detail below by embodiment, but the present invention is not limited to these examples.
Embodiment 1
The compound slow-release tablet of hydrochloric metformin 500mg pioglitazone hydrochloride 15mg
(1) preparation of diabecron sustained-release tablet core
Get metformin hydrochloride 500g, hydroxypropyl emthylcellulose (beautiful how elegant K100MCR) 200g, sodium carboxymethyl cellulose 75g, microcrystalline Cellulose 20g, mix homogeneously, add the 5%PVP alcoholic solution and make granule, add 0.5% magnesium stearate after the drying, compacting is in blocks, every hydrochloric metformin 500mg.Above-mentioned tablet is put in the coating pan, and with following coating solution coating, the coating weightening finish is to about 2～4%.
Eudragit?RS?100 13g
Eudragit?S?100 0.3g
Triethyl citrate 3.0g
Pulvis Talci 7.0g
Ethanol 400ml
(2) preparation of sealing coat
Get above-mentioned diabecron sustained-release tablet core and put in the coating pan, with following coating solution coating, the coating weightening finish is to about 1.5～2%.
Hydroxypropyl emthylcellulose E5 7.0g
Copolyvidone 4.5g
Differential silica gel 1.0g
Triethyl citrate 1.5g
Ethanol 200ml
(3) pioglitazone hydrochloride coating medicine-feeding
Take by weighing hydroxypropyl emthylcellulose E5, copolyvidone by recipe quantity, triethyl citrate, polysorbate80, add an amount of anhydrous alcohol solution, take by weighing pioglitazone hydrochloride and micropowder silica gel by recipe quantity, adding an amount of dehydrated alcohol and ultrasonic making is uniformly dispersed, merge above-mentioned solution, supply the dehydrated alcohol amount and stir.Use the ordinary coating pot, (2) gained coated tablet is carried out coating, the coating process should constantly stir coating solution, and coating meets the requirements to pioglitazone content and gets final product.
Pioglitazone 15g
Hydroxypropyl emthylcellulose E5 4.0g
Copolyvidone 4.0g
Differential silica gel 0.4g
Triethyl citrate 0.8g
Polysorbate80 7.5g
Ethanol 200ml
The conventional sheet stripping curve of pioglitazone hydrochloride stripping curve and pioglitazone hydrochloride is seen Fig. 2 in the compound recipe pioglitazone metformin slow releasing tablet; Metformin hydrochloride release profiles and diabecron sustained-release tablet release profiles are seen Fig. 3 in the compound recipe pioglitazone metformin slow releasing tablet.
As can be seen from the figure, the release of pioglitazone hydrochloride stripping and metformin hydrochloride is not disturbed mutually in the compound recipe pioglitazone metformin slow releasing tablet.
The tablet of other specifications of compound recipe pioglitazone metformin slow releasing tablet can be done suitable adjustment according to present embodiment and get final product.
Embodiment 2
The compound slow-release tablet of hydrochloric metformin 500mg glimepiride 1mg
(1) preparation of diabecron sustained-release tablet core
Preparation method is with embodiment 1.
(2) preparation of sealing coat
Get above-mentioned diabecron sustained-release tablet core and put in the coating pan, with following coating solution coating, the coating weightening finish is to about 1.5～2%.
Copolyvidone 12g
Micropowder silica gel 0.4g
PEG400 1.0g
Ethanol 200ml
(3) glimepiride coating medicine-feeding
Take by weighing hydroxypropyl emthylcellulose E5, copolyvidone by recipe quantity, PEG400, polysorbate80, add an amount of anhydrous alcohol solution, take by weighing glimepiride and micropowder silica gel by recipe quantity, adding an amount of dehydrated alcohol and ultrasonic making is uniformly dispersed, merge above-mentioned solution, supply the dehydrated alcohol amount and stir.Use the ordinary coating pot, (2) gained coated tablet is carried out coating, the coating process should constantly stir coating solution, and coating meets the requirements to glimepiride content and gets final product.
Glimepiride 1g
Copolyvidone 12g
Differential silica gel 0.4g
PEG400 1.0g
Polysorbate80 7.5g
Ethanol 200ml
The conventional sheet stripping curve of glimepiride stripping curve and glimepiride is seen Fig. 4 in the compound recipe glimepiride metformin slow releasing tablet; Metformin hydrochloride release profiles and diabecron sustained-release tablet release profiles are seen Fig. 5 in the compound recipe glimepiride metformin slow releasing tablet.
As can be seen from the figure, the release of glimepiride stripping and metformin hydrochloride is not disturbed mutually in the compound recipe glimepiride metformin slow releasing tablet.
The tablet of other specifications of compound recipe glimepiride metformin slow releasing tablet can be done suitable adjustment according to present embodiment and get final product.
Embodiment 3
The compound slow-release tablet that contains nicotinic acid 500mg simvastatin 5mg
(1) preparation of niacin sustained release label
Get nicotinic acid 500g, hydroxypropyl emthylcellulose (beautiful how elegant K15MCR) 180g, mix homogeneously adds the 5%PVP alcoholic solution and makes granule, adds 0.5% magnesium stearate after the drying, and compacting is in blocks, and every contains nicotinic acid 500mg.
(2) preparation of sealing coat
Get above-mentioned niacin sustained release label and put in the coating pan, with following coating solution coating, the coating weightening finish is to about 1.5%～2%.
Hydroxypropyl emthylcellulose E5 11.0g
Differential silica gel 0.6g
Triethyl citrate 1.1g
Ethanol 200ml
(3) simvastatin coating medicine-feeding
Take by weighing hydroxypropyl emthylcellulose E5, copolyvidone by recipe quantity, triethyl citrate, add an amount of anhydrous alcohol solution, take by weighing simvastatin, sodium lauryl sulphate and micropowder silica gel by recipe quantity, adding an amount of dehydrated alcohol and ultrasonic making is uniformly dispersed, merge above-mentioned solution, supply the dehydrated alcohol amount and stir.Use the ordinary coating pot, (2) gained coated tablet is carried out coating, the coating process should constantly stir coating solution, and coating meets the requirements to simvastatin content and gets final product.
Simvastatin 5g
Hydroxypropyl emthylcellulose E5 8.0g
Differential silica gel 0.4g
Triethyl citrate 0.8g
Sodium lauryl sulphate 5.0g
Ethanol 200ml
The conventional sheet stripping curve of simvastatin stripping curve and simvastatin is seen Fig. 6 in the compound simvastatin niacin sustained release tablet; Nicotinic acid release profiles and niacin slow-release tablet release profiles are seen Fig. 7 in the compound simvastatin niacin sustained release tablet.
As can be seen from the figure, the release of simvastatin stripping and nicotinic acid is not disturbed mutually in the compound simvastatin niacin sustained release tablet.
The compound preparation of the tablet of other specifications of compound simvastatin niacin sustained release tablet, niacin slow-release tablet and other his spit of fland drug regimens can be done suitable adjustment according to present embodiment and get final product.
Although the present invention has done detailed description in conjunction with its special embodiment, clearly concerning the skilled people in present technique field, still can make various changes and improvements, can not depart from spirit of the present invention and protection domain.
Claims (9)
1. multicomponent slow releasing preparation, it has pastille slow-release label, pastille rapid release clothing layer, it is characterized in that between pastille slow-release label and the pastille rapid release clothing layer sealing coat being arranged, this sealing coat is made up of high molecular weight water soluble polymer, the sealing coat weightening finish is about the 1-5% of label weight, preferred 1-2%.
2. the described multicomponent slow releasing preparation of claim 1, slow release label and rapid release clothing layer contained drug composition are different, select the big drug regimen of half-life difference especially for use, and the half-life of slow release label Chinese medicine is short, and the drug half-life in the rapid release clothing layer is long.
3. the described drug regimen of claim 2 can be selected from: metformin and pioglitazone, metformin and glimepiride, nicotinic acid and simvastatin.
4. the described high molecular weight water soluble polymer that is used to form sealing coat of claim 1-3 can be selected from one or more combination of water-soluble cellulose ether, water-soluble polyethylene radical derivative, alkylene oxide polymer; Wherein, water-soluble cellulose ether comprises methylcellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, sodium carboxymethyl cellulose; The water-soluble polyethylene radical derivative comprises polyvinylpyrrolidone, polyvinyl alcohol; Alkylene oxide polymer comprises Polyethylene Glycol, polypropylene glycol.
5. the described high molecular weight water soluble polymer that is used to form sealing coat of claim 4 can be selected from hydroxypropyl emthylcellulose, polyvinylpyrrolidone.
6. the described multicomponent slow releasing preparation of claim 1-5, its pastille rapid release clothing layer can be selected the high polymer identical with sealing coat for use.
7. the described pastille rapid release of claim 6 clothing layer can be united the use surfactant, comprises sodium lauryl sulphate, polysorbate, Polyethylene Glycol.Wherein special preferably sodium dodecyl sulfate, polysorbate80.
8. the described multicomponent slow releasing preparation of claim 1-7 can prepare sealing coat and rapid release pastille clothing layer by spray coating.
9. the multicomponent slow releasing preparation of claim 8, the stripping rapidly of the outer Chinese medicine of this slow releasing preparation, the internal layer Chinese medicine can slowly discharge, and does not disturb mutually.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102283076A CN102058557A (en) | 2009-11-18 | 2009-11-18 | Multicomponent sustained-release preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102283076A CN102058557A (en) | 2009-11-18 | 2009-11-18 | Multicomponent sustained-release preparation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102058557A true CN102058557A (en) | 2011-05-18 |
Family
ID=43994186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102283076A Pending CN102058557A (en) | 2009-11-18 | 2009-11-18 | Multicomponent sustained-release preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102058557A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285398A (en) * | 2013-06-28 | 2013-09-11 | 青岛黄海制药有限责任公司 | Compound preparation containing DPP-IV (dipeptidyl peptidase-IV) inhibitor and type-II diabetes medicine and preparation method thereof |
| CN103432128A (en) * | 2013-08-26 | 2013-12-11 | 中国人民解放军第150中心医院 | Method for compounding drug-containing layer of pioglitazone hydrochloride controlled-release pellet preparation |
| CN103432131A (en) * | 2013-09-11 | 2013-12-11 | 中国药科大学 | Compound preparation containing pioglitazone hydrochloride and metformin hydrochloride and preparing method thereof |
| CN103432129A (en) * | 2013-08-26 | 2013-12-11 | 中国人民解放军第150中心医院 | Method for compounding pioglitazone hydrochloride controlled-release pellet preparation |
| CN103462903A (en) * | 2013-08-26 | 2013-12-25 | 中国人民解放军第150中心医院 | Combination method and preparation process of pioglitazone hydrochloride sustained-release pellet preparation |
| CN106137999A (en) * | 2015-03-31 | 2016-11-23 | 深圳翰宇药业股份有限公司 | A kind of compound recipe pioglitazone Metformin Extended-release Tablets and preparation method thereof |
-
2009
- 2009-11-18 CN CN2009102283076A patent/CN102058557A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285398A (en) * | 2013-06-28 | 2013-09-11 | 青岛黄海制药有限责任公司 | Compound preparation containing DPP-IV (dipeptidyl peptidase-IV) inhibitor and type-II diabetes medicine and preparation method thereof |
| CN103285398B (en) * | 2013-06-28 | 2015-07-22 | 青岛黄海制药有限责任公司 | Compound preparation containing DPP-IV (dipeptidyl peptidase-IV) inhibitor and type-II diabetes medicine and preparation method thereof |
| CN103432128A (en) * | 2013-08-26 | 2013-12-11 | 中国人民解放军第150中心医院 | Method for compounding drug-containing layer of pioglitazone hydrochloride controlled-release pellet preparation |
| CN103432129A (en) * | 2013-08-26 | 2013-12-11 | 中国人民解放军第150中心医院 | Method for compounding pioglitazone hydrochloride controlled-release pellet preparation |
| CN103462903A (en) * | 2013-08-26 | 2013-12-25 | 中国人民解放军第150中心医院 | Combination method and preparation process of pioglitazone hydrochloride sustained-release pellet preparation |
| CN103432128B (en) * | 2013-08-26 | 2015-11-18 | 中国人民解放军第150中心医院 | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations medicated layer |
| CN103432129B (en) * | 2013-08-26 | 2016-01-27 | 中国人民解放军第150中心医院 | A kind of compound formulation of pioglitazone hydrochloride sustained-release pellet preparations |
| CN103462903B (en) * | 2013-08-26 | 2016-06-22 | 中国人民解放军第150中心医院 | A kind of preparation technology of pioglitazone hydrochloride sustained-release pellet preparations |
| CN103432131A (en) * | 2013-09-11 | 2013-12-11 | 中国药科大学 | Compound preparation containing pioglitazone hydrochloride and metformin hydrochloride and preparing method thereof |
| CN106137999A (en) * | 2015-03-31 | 2016-11-23 | 深圳翰宇药业股份有限公司 | A kind of compound recipe pioglitazone Metformin Extended-release Tablets and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Serratoni et al. | Controlled drug release from pellets containing water-insoluble drugs dissolved in a self-emulsifying system | |
| AU698360B2 (en) | Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application | |
| FI121620B (en) | Process for obtaining a controlled release formulation of an active substance | |
| RU2528095C2 (en) | Systems of film coating for preparations with immediate release, creating enhanced anti-moisture barrier, and substrates with such coating | |
| AU2004289223B2 (en) | Once daily dosage forms of trospium | |
| CN102058557A (en) | Multicomponent sustained-release preparation and preparation method thereof | |
| CN103228267A (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
| SK7612001A3 (en) | Controlled-release dosage forms comprising zolpidem or a salt thereof | |
| KR20080009213A (en) | Use of polymer mixtures for the production of coated pharmaceutical formulations and pharmaceutical formulation with mixed polymeric coating | |
| CN100361660C (en) | Levofloxacin slow release micropill, its preparation method and uses | |
| CA2967722A1 (en) | Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol | |
| JP2009541433A (en) | Pharmaceutical compositions for oral administration of omega polyene fatty acids, and one or more incompatible ingredients and the process of their preparation | |
| US20090004284A1 (en) | Controlled release tamsulosin hydrochloride formulation | |
| MX2011002364A (en) | Stable pharmaceutical formulation with limited discoloration. | |
| CN102048701B (en) | Pitavastatin calcium enteric sustained-release micropill preparation and preparation method thereof | |
| JPH02288821A (en) | Particle and medicine preparation coated with film containing agonist | |
| CN104800184B (en) | The smooth sustained release agent pieces of butanedioic acid furan Luo Qu | |
| CN102058544B (en) | Method for preparing enteric slow release pellet containing fenofibric acid choline salt | |
| EP1839649A1 (en) | Coated formulations for tolterodine | |
| JP3759949B2 (en) | Shielding agent and coating composition | |
| CN102755302B (en) | Delayed release preparation containing safe and reliable plasticizer and preparation method thereof | |
| CN101120931A (en) | Bezafibrate sustained-release composition | |
| US20080193524A1 (en) | Extended Release Venlafaxine Compositions | |
| CA2984235C (en) | Rivastigmine-containing sustained-release pharmaceutical composition | |
| CN104274387A (en) | Metoprolol slow-release composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110518 |